270 related articles for article (PubMed ID: 12954120)
21. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.
Hoffmann M; Vogelsang H; Kletter K; Zettinig G; Chott A; Raderer M
Gut; 2003 Mar; 52(3):347-51. PubMed ID: 12584214
[TBL] [Abstract][Full Text] [Related]
22. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
Kurokawa T; Yoshida Y; Kawahara K; Tsuchida T; Okazawa H; Fujibayashi Y; Yonekura Y; Kotsuji F
Int J Cancer; 2004 May; 109(6):926-32. PubMed ID: 15027127
[TBL] [Abstract][Full Text] [Related]
23. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors.
Koyama K; Okamura T; Kawabe J; Ozawa N; Torii K; Umesaki N; Miyama M; Ochi H; Yamada R
J Nucl Med; 2003 Mar; 44(3):353-8. PubMed ID: 12621000
[TBL] [Abstract][Full Text] [Related]
25. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
Zhuang H; Pourdehnad M; Lambright ES; Yamamoto AJ; Lanuti M; Li P; Mozley PD; Rossman MD; Albelda SM; Alavi A
J Nucl Med; 2001 Sep; 42(9):1412-7. PubMed ID: 11535734
[TBL] [Abstract][Full Text] [Related]
26. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
[TBL] [Abstract][Full Text] [Related]
27. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer.
Kitagawa Y; Sano K; Nishizawa S; Nakamura M; Ogasawara T; Sadato N; Yonekura Y
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):63-71. PubMed ID: 12483411
[TBL] [Abstract][Full Text] [Related]
29. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
[TBL] [Abstract][Full Text] [Related]
30. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
31. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
32. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
[TBL] [Abstract][Full Text] [Related]
34. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
35. Molecular imaging of proliferation in malignant lymphoma.
Buck AK; Bommer M; Stilgenbauer S; Juweid M; Glatting G; Schirrmeister H; Mattfeldt T; Tepsic D; Bunjes D; Mottaghy FM; Krause BJ; Neumaier B; Döhner H; Möller P; Reske SN
Cancer Res; 2006 Nov; 66(22):11055-61. PubMed ID: 17108145
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of 5-[
Yu HM; Chiu CH; Chen WT; Wu CH; Lin PY; Huang YY; Chen JH; Tzen KY; Shiue CY; Lin WJ
Appl Radiat Isot; 2019 Jun; 148():152-159. PubMed ID: 30959352
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of FDG PET in patients with cervical cancer.
Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
[TBL] [Abstract][Full Text] [Related]
38. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
39. [Positron emission tomography with 18F-FDG compared with proliferative activity of tumor cells in different subtypes of non-Hodgkin lymphoma].
Tiutin LA; Khodzsibekova MM; Pozharisskiĭ KM; Mukhina MS; Kostenikov NA; Il'in NV
Vopr Onkol; 2011; 57(6):748-52. PubMed ID: 22416392
[TBL] [Abstract][Full Text] [Related]
40. Quantification of local tumor response to fractionated radiation therapy for non-Hodgkin lymphoma using weekly 18F-FDG PET/CT imaging.
Keller H; Goda JS; Vines DC; Lockwood G; Tsang R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):850-8. PubMed ID: 19515502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
